Azab 250 is a semi-synthetic antibiotic, the first of a subclass azalides somewhat different in structure from classical macrolides.
Obtained by modifying 14-membered macrolides by inclusion of the nitrogen atom in the lactone ring between 9 and 10 carbon atoms, wherein the ring turns in a 15-membered. This restructuring leads to a significant increase in acid resistance of the drug – up to 300 times compared with erythromycin.
Action of azab 250
Antibacterial broad spectrum azalide, bacteriostatic. Communicating with the 50S-ribosomal subunit, inhibits peptidtranslokazu at the stage of translation, inhibits protein synthesis, inhibits the growth and reproduction of bacteria, in high concentrations has a bactericidal effect. It acts on the extra- and intracellular pathogens.
Infections of the upper respiratory tract and upper respiratory tract caused by susceptible pathogens: pharyngitis , tonsillitis , laryngitis , sinusitis , otitis media ; scarlet fever ; infections of the lower respiratory tract: pneumonia (including atypical , exacerbation of chronic) bronchitis ; infections of skin and soft tissues: erysipelas , impetigo , secondarily infected dermatoses ; Urinary tract infections caused by Chlamidia trachomatis: gonorrheal and negonoreyny urethritis , cervicitis ; Lyme disease (initial stage), peptic ulcer and 12 duodenal ulcer associated with of Helicobacter pylori (in a combination therapy).
Side effects of azab 250
Hypersensitivity (including macrolide), hepatic and / or renal failure .
From the digestive system: ingestion – diarrhea (5%), nausea (3%), abdominal pain (3%); 1% or less – flatulence , vomiting , melena , cholestatic jaundice , elevated “liver” transaminase ; In addition, in children – constipation , decreased appetite , gastritis ; candidiasis of the oral mucosa.
From the CCC: palpitations, chest pain (1% or less).
From the nervous system: dizziness, headache , drowsiness, sensorineural hearing loss , tinnitus ; in children – headache (in the treatment of otitis media ), hyperkinesia , anxiety , neurosis , disorders of sleep (1% or less).
From the urogenital system: vaginal candidiasis , nephritis (1% or less).
Allergic reactions : rash, hives , itching, angioneurotic edema ; at / in the introduction – bronchospasm (1% or less).
Local reactions: at / in the introduction – pain and inflammation at the injection site.
Other: asthenia , photosensitivity ; in children – conjunctivitis ; change flavor (1% or less).